SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jul 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a type of medication called SGLT2 inhibitors can help protect the brain and improve recovery in people who have had an acute ischemic stroke, which is a common type of stroke caused by a blockage in blood flow to the brain. Researchers want to see if adding this medicine to standard stroke care can help patients do better three months after their stroke.

Adults aged 18 and older who have recently (within 3 days) experienced this type of stroke and meet certain health criteria may be eligible to join. Participants should have a moderate level of stroke severity and be able to provide consent. People with certain conditions, like severe kidney or liver problems, very low or very high blood sugar, or recent use of this type of medication, will not be included. Those who join the study will receive either the SGLT2 inhibitor medicine along with usual care or standard care alone, and their recovery will be closely monitored over time. This study is not yet recruiting, but it aims to find new ways to help stroke patients recover better and reduce long-term disability.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Patients with acute ischemic stroke (AIS) within ≤ 3 days of onset, with no restrictions on reperfusion therapy
• • NIHSS score of 4-25 at the time of randomization
• • Pre-stroke mRS score ≤ 1
• • Signed informed consent form
• Exclusion Criteria:
• • Presence of intracranial hemorrhage at the time of randomization
• • BMI ≤ 18 kg/m²
• • Severe renal insufficiency (eGFR \< 30 mL/min) or severe liver impairment (Child-Pugh Class C liver function)
• • Type 1 diabetes mellitus
• • Blood glucose level \< 2.7 mmol/L or \> 22.2 mmol/L at the time of randomization
• • Systolic blood pressure \< 95 mmHg at the time of randomization
• • History of heart failure
• • Use of SGLT-2 inhibitors within 4 weeks prior to randomization
• • Intolerance to SGLT-2 inhibitors
• • Life expectancy \< 3 months
• • Pregnant or lactating women
• • Already enrolled in another clinical trial
• • Other conditions deemed inappropriate for inclusion by the investigator